Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate and Imiquimod
2012-003112-31Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Apr 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in actinic keratosis (AK) comparing Ingenol mebutate with Imiquimod (2 arms). Primary endpoint: Cumulative incidence of invasive squamous cell carcinoma in treatment field over 3 years. Started Apr 2013; status: completed.
02
Drugs
ingenol mebutateimiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2012-003112-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003112-31.